Posted in Uncategorized
At The Patent Baron®, our Grand Rapids, MI design patents lawyer believes that robust intellectual property enforcement is the backbone of innovation — whether you represent a giant pharmaceutical leader or advise a technology startup. The recent legal action by Novo Nordisk against Hims & Hers Health Inc. over alleged patent infringement in the obesity drug space encapsulates a turning point in how patent holders are asserting rights against copycats and compounded products.
This case is about more than just two companies; it highlights how critical patent strategy and enforcement are in an era where competitors and alternate distribution models increasingly test the limits of exclusivity.
The Heart Of The Dispute: Patent Rights And Compounded Drugs
Novo Nordisk, the maker of the blockbuster weight-loss medication Wegovy, filed a lawsuit accusing Hims of infringing on its patents protecting the active ingredient semaglutide — the same peptide used in both Wegovy and its sister diabetes drug Ozempic.
According to the complaint, Hims marketed and planned to sell “copycat” versions of the oral Wegovy pill and other compounded semaglutide products at significantly lower price points. While Hims later withdrew its copycat offering following regulatory pressure, Novo Nordisk’s suit continues, alleging that merely licensing compounded duplicates and mass marketing them violated its patent rights and harmed both patients and competitive fairness.
For IP practitioners, this lawsuit reinforces a core principle: patent rights extend not just to the finished product, but also to variations and formulations that depend on the patented invention — even when deployed through alternative models such as telehealth or compounding pharmacies. This can be particularly true when the active ingredient or delivery method falls squarely within the scope of granted claims.
Why This Matters For Patent Strategy
Patent Enforcement Isn’t Passive
Many clients view patents as “set-and-forget” rights once granted, but litigation like this underscores that enforcement must be a continuous strategy. At The Patent Baron®, we guide clients to watch not only filed applications, but also how competitors might work around or replicate core technologies — whether through compounding, reformulation, or marketing channels.
Compounded And Copycat Products Are Not Always Safe Havens
Some telehealth platforms and pharmacies argue that compounded products exist in a legal gray zone, especially when driven by patient access or price pressures. However, where patent rights clearly cover the underlying active ingredient or method of use, these are not necessarily safe harbors. Litigation from leading patent owners like Novo Nordisk signals that the industry and courts want clarity here.
Patent Strategy Ties To Regulatory Enforcement
In this dispute, the U.S. Food and Drug Administration also weighed in against unapproved compounded versions, underscoring how patent disputes can align with regulatory actions to protect public health and IP integrity simultaneously.
Lessons For IP Professionals
For patent counsel and corporate leaders, the Novo Nordisk vs. Hims case serves as a compelling example of how patents protect the economic life of innovation. It shows why a strong patent not only deters copycats but empowers rightful owners to enforce exclusivity decisively.
At The Patent Baron®, we recommend that clients:
- Monitor competitors’ formulation and marketing strategies closely
- Evaluate enforcement options early before copycats scale
- Partner patent strategy with regulatory intelligence
- Building Ironclad Patent-Driven Growth
A patent without enforcement is like a tower with no foundation. Whether you’re advising biotech, software, or consumer brands, enforcing patent rights protects not just revenue — it defends your client’s reputation, innovation trajectory, and competitive advantage.
If your business is navigating similar enforcement challenges or needs a more aggressive patent strategy, let The Patent Baron® PLLC help you fortify and enforce the IP that matters most.
Credits: Inspired by Bloomberg reporting on Novo Nordisk’s lawsuit against Hims & Hers over alleged patent infringement in the obesity drug market.
Disclaimer: This article is informational and does not constitute legal advice. Subscription to this blog does not establish an attorney-client relationship with The Patent Baron®. For legal advice on specific patent matters, consult qualified IP counsel.
